David W. Rusnak

5.6k total citations · 4 hit papers
25 papers, 3.5k citations indexed

About

David W. Rusnak is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David W. Rusnak has authored 25 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David W. Rusnak's work include HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). David W. Rusnak is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). David W. Rusnak collaborates with scholars based in United States, United Kingdom and Japan. David W. Rusnak's co-authors include Krystal J. Alligood, Tona M. Gilmer, Robert J. Mullin, Barry R. Keith, Edgar R. Wood, Karen Lackey, Scott H. Dickerson, Lisa M. Shewchuk, Glenn Spehar and Anne T. Truesdale and has published in prestigious journals such as Blood, Cancer Research and Oncogene.

In The Last Decade

David W. Rusnak

24 papers receiving 3.4k citations

Hit Papers

A Unique Structure for Ep... 2001 2026 2009 2017 2004 2006 2001 2002 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
    2004 881 citations Edgar R. Wood, Anne T. Truesdale et al. Cancer Research profile →
  2. Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
    2006 711 citations David W. Rusnak, Glenn Spehar et al. Cancer Research profile →
  3. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    2001 590 citations David W. Rusnak, Karen Lackey et al. PubMed profile →
  4. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    2002 548 citations Wenle Xia, Robert J. Mullin et al. Oncogene profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David W. Rusnak United States 17 2.3k 1.4k 947 882 595 25 3.5k
Krystal J. Alligood United States 12 1.6k 0.7× 1.3k 0.9× 683 0.7× 668 0.8× 388 0.7× 13 2.6k
Robert J. Mullin United States 19 1.9k 0.8× 1.2k 0.8× 729 0.8× 785 0.9× 258 0.4× 37 3.0k
Karen Lackey United States 21 1.3k 0.6× 1.3k 0.9× 448 0.5× 516 0.6× 883 1.5× 32 2.8k
Carolyn Discafani United States 23 1.4k 0.6× 1.4k 1.0× 357 0.4× 569 0.6× 872 1.5× 30 3.0k
Neil L. Spector United States 36 3.5k 1.5× 2.1k 1.5× 1.5k 1.5× 1.1k 1.2× 178 0.3× 83 5.2k
Charles Zacharchuk United States 27 1.6k 0.7× 1.5k 1.0× 538 0.6× 764 0.9× 178 0.3× 54 3.2k
Norma O’Donovan Ireland 36 2.3k 1.0× 2.2k 1.5× 561 0.6× 637 0.7× 251 0.4× 116 4.3k
Anne T. Truesdale United States 13 972 0.4× 1.1k 0.7× 291 0.3× 505 0.6× 404 0.7× 16 2.3k
Wenle Xia United States 23 1.9k 0.8× 1.3k 0.9× 881 0.9× 461 0.5× 104 0.2× 31 2.8k
Michele Sue‐Ann Woo United States 9 1.7k 0.7× 1.9k 1.3× 230 0.2× 1.5k 1.7× 455 0.8× 17 3.1k

Countries citing papers authored by David W. Rusnak

Since Specialization
Citations

This map shows the geographic impact of David W. Rusnak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Rusnak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Rusnak more than expected).

Fields of papers citing papers by David W. Rusnak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Rusnak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Rusnak. The network helps show where David W. Rusnak may publish in the future.

Co-authorship network of co-authors of David W. Rusnak

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Rusnak. A scholar is included among the top collaborators of David W. Rusnak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Rusnak. David W. Rusnak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mitra‐Kaushik, Shibani, et al.. (2023). Cloud security in a bioanalytical world: considerations for use of third-party cloud services for bioanalysis. Bioanalysis. 15(24). 1461–1468. 1 indexed citations
2.
3.
Ahene, Ago, David W. Rusnak, Susan Spitz, et al.. (2012). Ligand Binding Assays in the 21st Century Laboratory: Automation. The AAPS Journal. 14(1). 142–153. 6 indexed citations
4.
Waterson, Alex G., Kimberly G. Petrov, Keith R. Hornberger, et al.. (2009). Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(5). 1332–1336. 33 indexed citations
5.
Greshock, Joel, Jie Cheng, David W. Rusnak, et al.. (2008). Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. Molecular Cancer Therapeutics. 7(4). 935–943. 18 indexed citations
6.
Gilmer, Tona M., Krystal J. Alligood, David W. Rusnak, et al.. (2008). Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib. Cancer Research. 68(2). 571–579. 51 indexed citations
7.
Rheault, Tara, Thomas R. Caferro, Scott H. Dickerson, et al.. (2008). Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(3). 817–820. 72 indexed citations
8.
Hubbard, Robert D., Scott H. Dickerson, Robert Griffin, et al.. (2008). Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines. Bioorganic & Medicinal Chemistry Letters. 18(21). 5738–5740. 29 indexed citations
9.
10.
Petrov, Kimberly G., Yuemei Zhang, G. Stuart Cockerill, et al.. (2006). Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorganic & Medicinal Chemistry Letters. 16(17). 4686–4691. 144 indexed citations
11.
Wood, Edgar R., Anne T. Truesdale, Octerloney B. McDonald, et al.. (2004). A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib). Cancer Research. 64(18). 6652–6659. 881 indexed citations breakdown →
12.
Rusnak, David W., Zhihong Lai, Timothy J. Lansing, et al.. (2004). A simple method for predicting serum protein binding of compounds from IC 50 shift analysis for in vitro assays. Bioorganic & Medicinal Chemistry Letters. 14(9). 2309–2312. 12 indexed citations
13.
Gaul, Micheal D., Yu Guo, Karen Affleck, et al.. (2003). Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines. Bioorganic & Medicinal Chemistry Letters. 13(4). 637–640. 40 indexed citations
14.
Xia, Wenle, Robert J. Mullin, Barry R. Keith, et al.. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 21(41). 6255–6263. 548 indexed citations breakdown →
15.
16.
Alligood, Krystal J., Paul S. Charifson, Renae M. Crosby, et al.. (1998). The formation of a covalent complex between a dipeptide ligand and the src SH2 domain. Bioorganic & Medicinal Chemistry Letters. 8(10). 1189–1194. 13 indexed citations
17.
Kilpatrick, Katherine E., France Carrier, Martin L. Smith, et al.. (1995). The Production and Characterization of Murine Monoclonal Antibodies to Human Gadd45 Raised against a Recombinant Protein. Hybridoma. 14(4). 355–359. 9 indexed citations
18.
Carter, Charleata A., et al.. (1994). Alterations in the Localization of F-Actin, Fibronectin, and Thrombospondin Occur Prior to Neoplastic Transformation in Rat Tracheal Epithelial Cells. Experimental Cell Research. 212(1). 141–150. 8 indexed citations
19.
Ferriola, Patrice C., Alice Robertson, David W. Rusnak, Richard P. DiAugustine, & Paul Nettesheim. (1992). Epidermal growth factor dependence and TGFα autocrine growth regulation in primary rat tracheal epithelial cells. Journal of Cellular Physiology. 152(2). 302–309. 20 indexed citations
20.
Ferriola, Patrice C., Cheryl L. Walker, Alice Robertson, et al.. (1989). Altered Growth Factor Dependence and Transforming Growth Factor Gene Expression in Transformed Rat Tracheal Epithelial Cells. Molecular Carcinogenesis. 2(6). 336–344. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krystal J. Alligood Breakdown of academic impact, for papers by Robert J. Mullin Breakdown of academic impact, for papers by Karen Lackey Breakdown of academic impact, for papers by Carolyn Discafani Breakdown of academic impact, for papers by Neil L. Spector Breakdown of academic impact, for papers by Charles Zacharchuk Breakdown of academic impact, for papers by Norma O’Donovan Breakdown of academic impact, for papers by Anne T. Truesdale Breakdown of academic impact, for papers by Wenle Xia Breakdown of academic impact, for papers by Michele Sue‐Ann Woo
Rankless by CCL
2026